ABBV - AbbVie Inc
A biopharmaceutical leader best known for Humira — the world's best-selling drug — now pivoting its pipeline toward immunology, oncology, and neuroscience.
Finlify Score
26.5 / 100
Data Quality
FULL
Penalty
0.0
Sector
Health Care
Close Price
$221.59
-2.70%
52W Range
$181.73 - $244.81
Market Cap
$384.7B
-2.7%Compared to previous day
2026 Q1 Revenue
$15.0B
-9.7%Changes from last reporting quarter
2026 Q1 EPS
$0.39
Diluted shares
Analyst Rating
40 analysts in latest ratings feed
RSI
60.1
40-70 moderate
2Y Range Position
71%
-9.5% from high / +35.5% from low
Beta
0.30
Relative to market benchmark
MACD
0.38
MACD line 4.16 / signal line 3.78
Fundamental Trend
Growth 9.2Financial Health
Quality 47.6Data Quality
FULLValuation Reference
Price Chart
Close price, two-year source window
Finlify Score
AVOID26.5 / 100
Score History
Finlify Score and component trend
Financial Statements
Calendar year view. Figures are estimates only. For official figures, refer to the company website.
| 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | |
|---|---|---|---|---|
| Revenue | $15.0B-9.7% | $16.6B+5.3% | $15.8B+2.3% | $15.4B+15.6% |
| Gross Profit | - | - | - | - |
| Operating Income | $4.0B-12.2% | $4.5B+138.7% | $1.9B-61.1% | $4.9B+31.1% |
| Net Income | $695M-61.7% | $1.8B+876.3% | $186M-80.2% | $938M-27.1% |
Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.
AI Signal
Generated Jun 16, 2026
The Finlify signal for ABBV is AVOID, with a Finlify Score of 27.9/100, which appears to indicate a generally unfavorable quantitative outlook for the asset. This low score suggests potential concerns across various quantitative factors.
Technical
The extremely low Accumulation / Volume score of 3.0/100 suggests a lack of strong buying interest or potential selling pressure, despite the asset's 20-day return of 8.0% and 60-day return of 9.3%. The Relative Strength score of 42.8/100 may indicate underperformance compared to peers, while the RSI(14) at 66.0 suggests the asset is approaching overbought conditions.
Fundamentals
The Fundamental Trend score of 9.2/100 is notably low, which could indicate a deteriorating fundamental outlook for the company. Valuation metrics appear elevated, with a P/E ratio of 95.0x, a P/B ratio of 94.4x, and a P/S ratio of 6.6x, potentially suggesting the asset is trading at a premium. Despite these concerns, the Financial Quality score is moderate at 47.6/100, and the asset offers a dividend yield of 3.08% with a low beta of 0.3.
Macro Context
With inflation indicators such as CPI at 4.3% and Core PCE at 3.3% year-over-year, and a 10Y Treasury Yield of 4.5%, the prevailing higher interest rate environment may influence investor perception of asset valuations and the attractiveness of the dividend yield. The positive yield spread of 0.4% suggests a normal, albeit potentially tight, monetary policy stance.
Key Risks
- The extremely low Fundamental Trend score of 9.2/100 suggests a potentially deteriorating underlying business outlook.
- An Accumulation / Volume score of 3.0/100 indicates very weak buying interest or significant selling pressure, which may not support recent price gains.
- Elevated valuation multiples, including a P/E of 95.0x and P/B of 94.4x, could suggest the asset is trading at a significant premium.